Biomarkers of chronic inflammation and cognitive decline: A prospective observational study.

IF 4 Q1 CLINICAL NEUROLOGY Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-03-26 eCollection Date: 2024-01-01 DOI:10.1002/dad2.12568

Bhavna A Guduguntla, Alexi Vasbinder, Elizabeth Anderson, Tariq U Azam, Pennelope Blakely, Noah J Webster, Richard Gonzalez, Toni Atonucci, Judith L Heidebrink, Bruno Giordani, Laura Zahodne, Benjamin M Hampstead, Kristine J Ajrouch, Salim S Hayek

{"title":"Biomarkers of chronic inflammation and cognitive decline: A prospective observational study.","authors":"Bhavna A Guduguntla, Alexi Vasbinder, Elizabeth Anderson, Tariq U Azam, Pennelope Blakely, Noah J Webster, Richard Gonzalez, Toni Atonucci, Judith L Heidebrink, Bruno Giordani, Laura Zahodne, Benjamin M Hampstead, Kristine J Ajrouch, Salim S Hayek","doi":"10.1002/dad2.12568","DOIUrl":null,"url":null,"abstract":"We sought to determine whether the biomarkers of chronic inflammation predict cognitive decline in a prospective observational study. We measured baseline serum soluble urokinase plasminogen activator receptor (suPAR) and high sensitivity C-reactive protein (hs-CRP) levels in 282 participants of the University of Michigan Memory and Aging Project. Cognitive function was measured using the Montreal Cognitive Assessment (MoCA) and the Clinical Dementia Rating (CDR) scale for up to five time points. SuPAR and hs-CRP levels were not significantly higher in participants with mild cognitive impairment (n = 97) or dementia (n = 59), compared to those with normal cognitive function (n = 126). Overall, 14% of participants experienced significant cognitive decline over the study period. The change in MoCA or CDR scores over time did not differ significantly according to baseline suPAR or hs-CRP levels. Chronic systemic inflammation, as measured by serum suPAR or hs-CRP levels, is unlikely to contribute significantly to cognitive decline.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 1","pages":"e12568"},"PeriodicalIF":4.0000,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10964918/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.12568","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

We sought to determine whether the biomarkers of chronic inflammation predict cognitive decline in a prospective observational study. We measured baseline serum soluble urokinase plasminogen activator receptor (suPAR) and high sensitivity C-reactive protein (hs-CRP) levels in 282 participants of the University of Michigan Memory and Aging Project. Cognitive function was measured using the Montreal Cognitive Assessment (MoCA) and the Clinical Dementia Rating (CDR) scale for up to five time points. SuPAR and hs-CRP levels were not significantly higher in participants with mild cognitive impairment (n = 97) or dementia (n = 59), compared to those with normal cognitive function (n = 126). Overall, 14% of participants experienced significant cognitive decline over the study period. The change in MoCA or CDR scores over time did not differ significantly according to baseline suPAR or hs-CRP levels. Chronic systemic inflammation, as measured by serum suPAR or hs-CRP levels, is unlikely to contribute significantly to cognitive decline.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

慢性炎症和认知能力下降的生物标志物：前瞻性观察研究

我们试图在一项前瞻性观察研究中确定慢性炎症的生物标志物是否能预测认知能力的下降。我们测量了密歇根大学记忆与衰老项目 282 名参与者的血清可溶性尿激酶纤溶酶原激活物受体 (suPAR) 和高敏 C 反应蛋白 (hs-CRP) 的基线水平。认知功能采用蒙特利尔认知评估（MoCA）和临床痴呆评级（CDR）量表进行测量，测量时间长达五个时间点。与认知功能正常者（126 人）相比，轻度认知障碍参与者（97 人）或痴呆参与者（59 人）的 SuPAR 和 hs-CRP 水平并没有明显升高。总体而言，14%的参与者在研究期间出现了明显的认知功能下降。随着时间的推移，MoCA或CDR评分的变化与基线suPAR或hs-CRP水平没有显著差异。以血清suPAR或hs-CRP水平衡量的慢性全身性炎症不太可能对认知能力下降产生重大影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.